C13Efficacy in Cancer Versus Non-cancer Patients Treated with Methylnaltrexone: An Analysis of Two Placebo-controlled Studies

Methylnaltrexone (MNTX, Relistor ®) inhibits opioid peripheral adverse effects. This post hoc analysis evaluated pooled data from 2 randomized, double-blind studies and open-label extensions of adults with advanced illness and opioid-induced constipation.
Source: Pain Management Nursing - Category: Nursing Authors: Source Type: research

Related Links:

Subcutaneous (SC) methylnaltrexone (MNTX, Relistor ®) is approved for opioid-induced constipation (OIC) in adults with chronic noncancer pain and OIC in adults with advanced illness or with active cancer who require opioid dosage escalation for palliative care. This post hoc analysis evaluated data pooled from 3 randomized studies of patients with advanced illness and OIC.
Source: Pain Management Nursing - Category: Nursing Authors: Source Type: research
Abstract OBJECTIVES: To investigate racial differences in implementation of 11 evidence-based cancer pain management strategies in a matched sample of patients in hospice. SAMPLE & SETTING: 32 African American and 32 Caucasian American older adults (aged 65 years or older) with cancer pain receiving hospice care in the midwestern United States. METHODS & VARIABLES: Matched cohort secondary data analysis of postintervention data in a cluster randomized controlled trial was used. Main outcomes are the summative and individual Cancer Pain Practice Index scores. RESULTS: There were few statistic...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
RARITAN, NJ, February 10, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of DARZALEX® (daratumumab) in combination with Kyprolis® (carfilzomib) and dexamethasone (DKd) for relapsed/refractory multiple myeloma. The sBLA is supported by results from the Phase 3 CANDOR study, which compared treatment with DKd to carfilzomib and dexamethasone (Kd) in patients with multiple myeloma who relapsed after one to three prior lines of therapy. “Wh...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Buprenorphine is widely used as a treatment for patients with opioid use disorders, but has also been shown to be an effective treatment for cancer and neuropathic pain, with unique pharmacologic properties that give it several advantages over traditional opioids. Buprenorphine is associated with less analgesic tolerance, and is less likely to cause respiratory depression and constipation than other opioids. Buprenorphine also does not cause immunosuppression, sphincter of Oddi dysfunction, or hypogonadism like traditional opioids.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
CONCLUSIONS: OIC was found in almost all evaluations of weak or strong opioidusers (97 percent); moderate to severe OIC was found in 72 percent of the evaluations. Cancer patients were associated with severe constipation. Macrogol was superior to other laxatives. In our experience, macrogol relieved constipation in those on the combination of oxycodone and naloxone and in those on fentanyl patches. Lactulose and glycerol suppositories were associated with severe constipation. PMID: 31849029 [PubMed - in process]
Source: Journal of Opioid Management - Category: Addiction Tags: J Opioid Manag Source Type: research
Many patients who have cancer consider opioid-induced constipation (OIC) to be a burdensome side effect of opioid treatment.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Tags: Original Article Source Type: research
Many patients who have cancer consider opioid-induced constipation (OIC) to be a burdensome side effect of opioid treatment.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Source Type: research
CONCLUSIONS: TR-HIFU therapy for posterior DIE is feasible. It could be an interesting minimally invasive alternative to surgery for the treatment of rectosigmoid endometriosis if its efficacy and safety is confirmed. This article is protected by copyright. All rights reserved. PMID: 31788875 [PubMed - as supplied by publisher]
Source: The Ultrasound Review of Obstetrics and Gynecology - Category: Radiology Authors: Tags: Ultrasound Obstet Gynecol Source Type: research
Publication date: Available online 25 November 2019Source: Surgery (Oxford)Author(s): Shelly Griffiths, Damian G. GlancyAbstractIntestinal obstruction is a common surgical emergency, accounting for up to 20% of admissions with acute abdominal pain. Of these, 80% will have small bowel obstruction, the most common cause being adhesions. Colorectal cancer is the most common cause of large bowel obstruction. The cardinal features of obstruction are abdominal pain, vomiting, distension and absolute constipation. Initial management comprises adequate fluid resuscitation, decompression with a nasogastric tube and early identifica...
Source: Surgery (Oxford) - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Constipation | Nurses | Nursing | Pain | Pain Management | Study